Skip to main content

Table 1 Baseline demographics of patients with and without concomitant memantine use

From: Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study

  Memantine No memantine All  
Placebo Galantamine Placebo Galantamine Memantine No memantine p value
N 245 251 776 773 496 1549  
Sex
 Women (%) 60.4 67.3 65.2 64.9 63.9 65.1 0.7976χ
Age (years)
 Mean (SD) 74.2 (8.7) 73.8 (8.8) 72.8 (8.6) 72.7 (8.9) 74.0 (8.76) 72.8 (8.76) 0.008t
MMSE
 Mean (SD) 18.4 (4.2) 18.0 (4.1) 19.1 (4.0) 19.4 (4.1) 18.2 (4.16) 19.2 (4.02) 0.0001t
DAD
 Mean (SD) 59.0 (23.3) 57.0 (23.7) 61.5 (20.3) 63.4 (20.7) 58.0 (23.49) 62.5 (20.52) 0.0001t
AD duration (years)
 Mean (SD) 0.8 (1.3) 1.1 (1.7) 0.8 (1.7) 0.7 (1.3) 0.95 (1.50) 0.75 (1.57) 0.0127t
Prior therapy
 Cholinomimetic use (%) 23.3 23.5 16.0 13.3 23.4 14.7 0.0001χ
Nursing home placement
N 116 101 312 305 217 617  
 Cases, n (%) 10 (8.6) 3 (3.0) 14 (4.5) 13 (4.3) 13 (6.0) 27 (4.4) 0.3507χ
  1. χChi-square analysis
  2. t t test
  3. AD Alzheimer’s disease, DAD disability assessment for dementia, MMSE mini–mental state examination, SD standard deviation